Dr. Cheifetz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
330 Brookline Ave
Beth Israel Deaconess Medical Center
Boston, MA 02215Phone+1 617-667-2082
Education & Training
- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalFellowship, Gastroenterology, 2003 - 2004
- Yale-New Haven Medical CenterFellowship, Gastroenterology, 2001 - 2004
- Yale-New Haven Medical CenterResidency, Internal Medicine, 1997 - 2000
- Weill Cornell MedicineClass of 1997
Certifications & Licensure
- MA State Medical License 2004 - 2025
- CT State Medical License 2000 - 2005
- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Boston Magazine Castle Connolly, 2008-2013
- Fellow (AGAF) American Gastroenterological Association, 2012
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
- Join now to see all
Clinical Trials
Publications & Presentations
PubMed
- Small-Molecule Neutrophil Modulator ADS051 Is Safe and Well-Tolerated in a Phase 1 Single Ascending Dose Study.Adam S Cheifetz, Jessica R Allegretti, Megan Quintas, Bharat Dixit, Ronald Farquhar
The American Journal of Gastroenterology. 2024-11-26 - Morning Salivary Cortisol Has a Positive Correlation with GAD-7 Scores in Patients with Ulcerative Colitis.Cristina M Castro, Aditya Mithal, Tina Deyhim, Loren G Rabinowitz, Olawande Olagoke
Journal of Clinical Medicine. 2024-11-08 - 3 citationsRisankizumab Concentration but not IL-22 Levels Are Associated With Clinical and Biochemical Remission in Patients With Crohn's Disease.Xavier Roblin, Estelle Moschetti, Mathilde Barrau, Adam S Cheifetz, Konstantinos Papamichael
Clinical Gastroenterology and Hepatology. 2024-11-01
Journal Articles
- Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel DiseaseByron P Vaughn, Adam S Cheifetz, Digestive Diseases and Sciences
Lectures
- Advances in Gastroenterology - 2013Harvard Medical School ,Department Of Continuing Education, Boston, Massachusetts - 6/10/2013
- Gastroenterology in the 21st Century: Optimizing Patient OutcomesOMICS Publishing Group, Boston, Massachusetts - 5/7/2013
Other
- Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel diseaseCheifetz AS, Cullen GJ
http://www.uptodate.com/contents/sulfasalazine-and-5-aminosalicylates-in-the-treatment-of-inflammato
UpToDate, Wolters Kluwer Health - 2012-12-06
Press Mentions
- Dealing with Crohn's Disease During PregnancyJuly 28th, 2020
- Top in GI: Telehealth, IBD Treatment SelectionJuly 24th, 2020
- Bacainn Therapeutics Announces IND Clearance for BT051 and Initiation of Phase 1 Clinical Trial, Bacainn’s First Clinical Candidate for the Treatment of Ulcerative ColitisJune 9th, 2020
- Join now to see all
Professional Memberships
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: